Patients with type 2 diabetes mellitus often require multifactorial pharmacological treatment
due to different comorbidities. An increasing number of concomitantly taken medications …

The aim of this work was to review studies in which genetic variants were assessed with
respect to metabolic response to treatment with novel glucose-lowering drugs: dipeptidyl …

OBJECTIVE Sulfonylureas, the first available drugs for the management of type 2 diabetes,
remain widely prescribed today. However, there exists significant variability in glycemic …

Virtual small molecule libraries are valuable resources for identifying bioactive compounds
in virtual screening campaigns and improving the quality of libraries in terms of …

Genetic variation in the pharmacokinetics of metoprolol and torsemide due to
polymorphisms in CYP2D6, CYP2C9, and OATP1B1 has been extensively studied …

The biomedical research sector in Saudi Arabia has recently received special attention from
the government, which is currently supporting research aimed at improving the …

Purpose Sulphonylureas (SU) are widely used in the management of type 2 diabetes. We
investigated the influence of CYP2C9, KCNJ11 and ABCC8 polymorphisms on the response …

Introduction: Sulfonylurea antidiabetics are insulin secretogogues useful in the treatment of
type 2 diabetic patients. The probability of adverse drug interactions is high in patients taking …

Polymorphism in cytochrome P450 (CYP) 2C9 enzyme is known to cause significant inter-
individual differences in drug response and occurrence of adverse drug reactions. Different …

The therapeutic use of glimepiride and gliclazide shows substantial inter-individual variation
in pharmacokinetics and pharmacodynamics in human populations, which might be caused …